The National Institutes of Health’s (NIH) unit National Cancer Institute (NCI) and the Children’s Oncology Group (COG) have initiated patient enrolment in a paediatric Phase II clinical trial to evaluate targeted cancer medicines.

The NCI-COG Pediatric Molecular Analysis for Therapy Choice (Paediatric MATCH) trial is designed to study the efficacy of more than eight targeted therapies in children and adolescents suffering from solid tumours with specific genetic mutations.

Each investigational candidate will target a predefined set of genetic mutations and aim to match the molecular abnormalities in a patient’s tumours.

Designed to initially comprise six treatment arms, the trial will recruit subjects whose disease has progressed or not responding after standard treatment.

NCI acting director Douglas Lowy said: “There aren’t any other cancer trials of this scale exploring targeted treatments for children whose cancers have specific genetic abnormalities.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Precision medicine trials like Paediatric MATCH have the potential to accelerate progress in identifying more effective treatments for children with cancer.”

"Precision medicine trials like Paediatric MATCH have the potential to accelerate progress in identifying more effective treatments for children with cancer."

Patients will first undergo a screening study, under which relapsed tumour samples are subjected to DNA and RNA sequencing to identify genetic abnormalities that could be a target for one of the study candidates.

The sample screening will be performed using a single test that can detect alterations in more than 160 cancer-associated genes at a time.

Upon detection of the abnormality and a matching targeted drug, patients will then be enrolled into the trial depending on the eligibility criteria.

Trial investigators expect that 200-300 patients will have to be screened per year as cancer mutations matching the study drugs’ target are estimated to be present in about 10% of total tumours from affected children and adolescents.


Image: NCI-COG Paediatric MATCH trial will incorporate more than eight different study drugs. Photo: courtesy of National Institutes of Health.